letrozole has been researched along with Osteoporosis in 14 studies
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zoledronic acid prevents bone loss in postmenopausal women with osteoporosis/osteopenia starting letrozole and is associated with improvements in BMD." | 9.14 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. ( Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA, 2010) |
| "This study was designed to explore whether zoledronic acid could prevent expected loss of bone mineral density (BMD) in postmenopausal women with pre-existing osteopenia or osteoporosis who were initiating adjuvant letrozole therapy for primary breast cancer." | 7.83 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. ( Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N, 2016) |
| " Weight, height, prior hormone replacement therapy, and hysterectomy were positively correlated with BMD; the correlation was negative for letrozole arms (B/C/D versus A), known osteoporosis, time on trial, age, chemotherapy, and smoking." | 7.78 | Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). ( Aebi, S; Berthod, G; Brauchli, P; Genton, C; Giobbie-Hurder, A; Huober, J; Lüthi, J; Pagani, O; Schönenberger, A; Simcock, M; Thürlimann, B; Zaman, K, 2012) |
| "Zoledronic acid prevents bone loss in postmenopausal women with osteoporosis/osteopenia starting letrozole and is associated with improvements in BMD." | 5.14 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy. ( Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA, 2010) |
| "The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer." | 4.84 | Safety of aromatase inhibitors in the adjuvant setting. ( Perez, EA, 2007) |
| "During recent years the development of hormone therapy for the treatment breast neoplasms has seen, in addition to classic aspecific antiestrogens (AE) like tamoxifen (TAM) and to a lesser extent toremifen, a major development of new molecules divided into two groups: the first is the so-called selective estrogen receptor modulators (SERMs), the most important of which is Raloxifen, which mediate estrogen-agonist effects in some tissues and estrogen-antagonist effects in others; the second group includes the aromatase inhibitors (AI), important enzymes for peripheral estrogen conversion." | 4.81 | [Antiestrogen therapy in the treatment of breast neoplasms]. ( Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G, 2002) |
| "This study was designed to explore whether zoledronic acid could prevent expected loss of bone mineral density (BMD) in postmenopausal women with pre-existing osteopenia or osteoporosis who were initiating adjuvant letrozole therapy for primary breast cancer." | 3.83 | Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up. ( Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N, 2016) |
| " Weight, height, prior hormone replacement therapy, and hysterectomy were positively correlated with BMD; the correlation was negative for letrozole arms (B/C/D versus A), known osteoporosis, time on trial, age, chemotherapy, and smoking." | 3.78 | Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). ( Aebi, S; Berthod, G; Brauchli, P; Genton, C; Giobbie-Hurder, A; Huober, J; Lüthi, J; Pagani, O; Schönenberger, A; Simcock, M; Thürlimann, B; Zaman, K, 2012) |
| "Postmenopausal women with early breast cancer (EBC) are already at risk for bone loss, osteoporosis and fracture as they age because of declining estrogen levels." | 2.46 | Women and bone health: maximizing the benefits of aromatase inhibitor therapy. ( Tang, SC, 2010) |
| "University of Colorado Cancer Center breast cancer patients treated with aromatase inhibitor therapy during July 2005 through July 2006 were studied." | 1.35 | Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors. ( Gibson, K; O'Bryant, CL, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Coco-Martín, MB | 1 |
| Leal-Vega, L | 1 |
| Blázquez-Cabrera, JA | 1 |
| Navarro, A | 1 |
| Moro, MJ | 1 |
| Arranz-García, F | 1 |
| Amérigo, MJ | 1 |
| Sosa-Henríquez, M | 1 |
| Vázquez, MÁ | 1 |
| Montoya, MJ | 1 |
| Díaz-Curiel, M | 1 |
| Olmos, JM | 1 |
| Ruiz-Mambrilla, M | 1 |
| Filgueira-Rubio, J | 1 |
| Pérez-Castrillón, JL | 1 |
| Zhang, D | 1 |
| Li, X | 1 |
| Pi, C | 1 |
| Cai, L | 1 |
| Liu, Y | 1 |
| Du, W | 1 |
| Yang, W | 1 |
| Xie, J | 1 |
| Küpeli Akkol, E | 1 |
| İlhan, M | 1 |
| Ayşe Demirel, M | 1 |
| Keleş, H | 1 |
| Tümen, I | 1 |
| Süntar, İ | 1 |
| Majithia, N | 1 |
| Atherton, PJ | 2 |
| Lafky, JM | 1 |
| Wagner-Johnston, N | 1 |
| Olson, J | 1 |
| Dakhil, SR | 2 |
| Perez, EA | 3 |
| Loprinzi, CL | 2 |
| Hines, SL | 2 |
| Khachidze, N | 1 |
| Giorgadze, E | 1 |
| Tsagareli, M | 1 |
| Gibson, K | 1 |
| O'Bryant, CL | 1 |
| Gheita, TA | 1 |
| Ezzat, Y | 1 |
| Sayed, S | 1 |
| El-Mardenly, G | 1 |
| Hammam, W | 1 |
| Sloan, JA | 1 |
| Johnson, DB | 1 |
| Reddy, PS | 1 |
| Dalton, RJ | 1 |
| Mattar, BI | 1 |
| Tang, SC | 1 |
| Zaman, K | 1 |
| Thürlimann, B | 1 |
| Huober, J | 1 |
| Schönenberger, A | 1 |
| Pagani, O | 1 |
| Lüthi, J | 1 |
| Simcock, M | 1 |
| Giobbie-Hurder, A | 1 |
| Berthod, G | 1 |
| Genton, C | 1 |
| Brauchli, P | 1 |
| Aebi, S | 1 |
| Li, F | 1 |
| Chow, S | 1 |
| Cheung, WH | 1 |
| Chan, FL | 1 |
| Chen, S | 1 |
| Leung, LK | 1 |
| Gasser, JA | 1 |
| Green, JR | 1 |
| Shen, V | 1 |
| Ingold, P | 1 |
| Rebmann, A | 1 |
| Bhatnagar, AS | 1 |
| Evans, DB | 1 |
| Alba, E | 1 |
| Ragonesi, G | 1 |
| Colla, F | 1 |
| Mazzoleni, A | 1 |
| Farina, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Zoledronic Acid for Treatment of Osteopenia and Osteoporosis in Women With Primary Breast Cancer Undergoing Adjuvant Aromatase Inhibitor (Letrozole) Therapy[NCT00436917] | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | |||
| A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors[NCT00004205] | Phase 3 | 8,028 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change: BMD values at year 1 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 1 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 5.66 |
Change: BMD values at year 2 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 2 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 10.47 |
Change: BMD values at year 3 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 3 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 8.44 |
Change: BMD values at year 4 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 4 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 4.49 |
Change: BMD values at year 5 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 5 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 4.54 |
Change: BMD values at twelve months post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 1 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 2.66 |
Change: BMD values at year 2 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 2 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 4.94 |
Change: BMD values at year 3 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 3 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 6.20 |
Change: BMD values at year 4 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 4 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 6.99 |
Change: BMD values at year 5 post study entry minus BMD values at baseline, expressed as a percentage of the baseline value. (NCT00436917)
Timeframe: Baseline and 5 year
| Intervention | Percentage of the baseline value (Mean) |
|---|---|
| Zoledronic Acid | 11.71 |
Adverse events were assessed per NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Grade 1=Mild, Grade 2=Moderate. (NCT00436917)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 Arthralgia | Grade 2 Arthralgia | Grade 3 Arthralgia | Grade 1 Creatinine Increase | Grade 2 Creatinite increase | Grade 2 Desquamating Rash | Grade 2 Headache | Grade 2 Hot flashes | Grade 1 Nausea | Grade 3 Pain in extremity | Grade 1 Fever | Grade 1 Vomiting | Grade 1 Musculoskeletal disorder | Grade 2 Urogenital disorder | |
| Zoledronic Acid | 7 | 4 | 1 | 7 | 2 | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 1 | 1 |
4 reviews available for letrozole and Osteoporosis
| Article | Year |
|---|---|
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adj | 2017 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Br | 2002 |
1 trial available for letrozole and Osteoporosis
| Article | Year |
|---|---|
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Brea | 2010 |
9 other studies available for letrozole and Osteoporosis
| Article | Year |
|---|---|
Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry.
Topics: Bone Density Conservation Agents; Humans; Letrozole; Longitudinal Studies; Osteoporosis; Osteoporoti | 2023 |
Osteoporosis-decreased extracellular matrix stiffness impairs connexin 43-mediated gap junction intercellular communication in osteocytes.
Topics: Animals; Cell Communication; Connexin 43; Disease Models, Animal; Extracellular Matrix; Gap Junction | 2020 |
Thuja occidentalis L. and its active compound, α-thujone: Promising effects in the treatment of polycystic ovary syndrome without inducing osteoporosis.
Topics: Animals; Bicyclic Monoterpenes; Blood Glucose; Catalase; Estradiol; Female; Glutathione Peroxidase; | 2015 |
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Topics: Adjuvants, Pharmaceutic; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density C | 2016 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic | 2008 |
Musculoskeletal manifestations in patients with malignant disease.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Comb | 2010 |
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neopla | 2012 |
The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Citrus; Es | 2013 |
A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats.
Topics: Animals; Aromatase Inhibitors; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; B | 2006 |